Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), Anders Österborg(Karolinska University Hospital), Thomas Olin(Kancera (Sweden))
Cited by 11
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312